Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: The present invention relates to single thread composite fibers comprising at least one binder and at least one active catalyst for the capture and degradation of chemical threats such as chemical warfare agents (CWA), biological warfare agents, and toxic industrial chemicals (TIC) and a method for producing the same. The invention fibers are applicable to the fields of protective garments, filtration materials, and decontamination materials.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: E-selectin ligands which are useful for the synthesis of E-selectin ligand-bearing carriers, wherein said E-selectin ligand-bearing carriers are directly or indirectly linked to or associated with at least one therapeutic agent, diagnostic agent, imaging agent, or radiopharmaceutical are described herein.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are dessorbed and pharmaceutical compositions comprising at least one of the same.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are desorbed and pharmaceutical compositions comprising at least one of the same.

Abstract: Techniques are disclosed for promulgating service information and topology information in a network in a high availability manner. An example device is configured to create a first service and topology exchange protocol (STEP) document. The first STEP document includes service information and topology information. The example device is configured to send the first STEP document to a first STEP repository for forwarding to at least one subscribing network device. The example device is also configured to send the first STEP document to a second STEP repository for forwarding to the at least one subscribing network device.

Abstract: CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described.

Abstract: CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The ligands have formula (I) below.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent are described.

Abstract: Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition N associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, multimeric glycomimetic inhibitors of E-selectins, galectin-3, and/or CXCR4 chemokine receptors and their use for treating and/or preventing inflammatory diseases, fibrosis, and cancers are disclosed. Formula (I).

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: A network device is configured to associate a tenant of a plurality of tenants with a virtual routing and forwarding (VRF) instance of a plurality of VRF instances. The network device receives a packet comprising metadata specifying a tenant identifier for the tenant. The network device identifies, based on the tenant identifier specified by the metadata, the VRF instance associated with the tenant. The network device retrieves one or more routes from a routing information base (RIB) of the VRF instance associated with the tenant and forwards the packet toward a destination via the one or more routes.

Abstract: A process is provided for the synthesis of an intermediate of Formula 15 which is useful in the synthesis of E-selectin inhibitors. Also provided are useful intermediates obtained from the process.

Abstract: Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding are described herein. For example, multimeric selectin modulators and their use are described, wherein the multimeric selectin modulators comprise a glycomimetic linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).

Abstract: Techniques are described for a router providing metric-based multi-hop path selection. For example, a first router of a plurality of routers receives a plurality of network performance metrics for a plurality of links interconnecting the plurality of routers. The plurality of links form a plurality of multi-hop paths through the plurality of routers to a service instance. The router determines, based on the plurality of network performance metrics for the plurality of links, an end-to-end performance of each of the plurality of multi-hop paths. The router selects a multi-hop path over which to forward traffic associated with the session based on the end-to-end performance of each of the plurality of multi-hop paths and one or more performance requirements for a service associated between a session between a client device and the service instance. The router forwards the traffic to the service instance along the selected multi-hop path.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.